Fibromyalgia Therapeutics

Fibromyalgia Therapeutics

Global Fibromyalgia Therapeutics Market to Reach US$3.8 Billion by 2030

The global market for Fibromyalgia Therapeutics estimated at US$3.1 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiepileptics Drug Class, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Antidepressants Drug Class segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$829.3 Million While China is Forecast to Grow at 5.0% CAGR

The Fibromyalgia Therapeutics market in the U.S. is estimated at US$829.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$736.2 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Fibromyalgia Therapeutics - Key Trends and Drivers

Fibromyalgia is a chronic condition that significantly impacts the quality of life of about 4 million adults in the United States, primarily affecting women, though not exclusively. It is characterized by widespread musculoskeletal pain accompanied by fatigue, cognitive issues often referred to as "fibro fog," sleep disturbances, and heightened sensitivity to stimuli. The diagnosis of fibromyalgia is complex, typically involving a thorough assessment of patient history, symptom checks, and the exclusion of other potential conditions, given there are no definitive tests for fibromyalgia. The condition is often related to genetic factors, with a noticeable prevalence in families, and can be triggered by significant stress or traumatic events. Current understanding and management of fibromyalgia require a broadening of public and professional perception to better support those affected by this debilitating condition.

The therapeutic approach to managing fibromyalgia is multifaceted, focusing on alleviating symptoms while addressing the underlying irregularities in pain processing by the central nervous system. FDA-approved medications like pregabalin and duloxetine are commonly prescribed to manage pain and mood symptoms associated with fibromyalgia. Non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and corticosteroids, however, are generally ineffective. Other treatments include gabapentinoids for nerve pain, sedatives for sleep disturbances, and SNRIs and SSRIs for managing psychological symptoms. Non-pharmacological treatments such as physical therapy, acupuncture, cognitive behavioral therapy, and lifestyle modifications like dietary changes are also essential components of a comprehensive treatment plan. These strategies aim to improve overall physical function, reduce pain, and enhance quality of life for fibromyalgia patients.

The growth in fibromyalgia therapeutics is driven by several key factors. Advancements in diagnostic technologies have improved the accuracy and timeliness of fibromyalgia diagnosis, enhancing the application of targeted treatments. The integration of AI and machine learning in healthcare facilitates personalized treatment plans, optimizing therapy outcomes. Wearable health technology that monitors vital health metrics has become instrumental in customizing treatment approaches based on real-time data. Additionally, increased availability of telemedicine services has expanded access to care, particularly for patients in remote areas, improving adherence to treatment regimens. There is also a notable shift towards non-pharmacological treatments, reflecting a growing patient preference for alternative therapies. Furthermore, educational initiatives and increased awareness are crucial in promoting early diagnosis and effective management of fibromyalgia. Regulatory support and favorable reimbursement policies also play significant roles in encouraging the adoption of innovative therapies, making treatments more accessible and affordable. Collectively, these factors are shaping a more dynamic, integrated, and patient-centric landscape in fibromyalgia therapeutics.

Select Competitors (Total 22 Featured) -

• Allergan plc
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Company Limited
• Eli Lilly and Company
• Innovative Med Concepts Inc.
• Pfizer Inc.
• SWITCHBIOTECH LLC
• Zynerba Pharmaceuticals Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.